BRIEF: Deciphera bags a $52M round to back its cancer drug pipeline work
Waltham, MA-based Deciphera Therapeutics has been carefully tracking the early-stage progress it’s been making with its lead drug, a pan-KIT and PDGFR inhibitor dubbed DCC …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
